Zymeworks ZYME Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -140.4%-53.0pp | -87.3%-34.8pp | -52.5%+14.8pp | -67.3%+66.5pp | -133.8%+45.9pp | |
| Net margin | -126.3%-49.8pp | -76.6%-29.4pp | -47.2%+12.8pp | -60%+61.8pp | -121.7%+39.1pp | |
| Returns | ||||||
| Return on equity | -42%-15.3pp | -26.7%-8.3pp | -18.5%+1.4pp | -19.9%+9.9pp | -29.8%+0.7pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×-0.1× | 0.3×0.0× | 0.3×0.0× | 0.3×+0.1× | 0.2×0.0× | |
| Liquidity | ||||||
| Current ratio | 10.8×+4.9× | 5.9×-1.1× | 6.9×-0.8× | 7.7×+3.0× | 4.7×+1.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $2.19-38.5% | $3.56-15.7% | $4.22-2.3% | $4.32+0.1% | $4.32-3.2% | |
| Valuation | ||||||
| Market capitalization | $1.86B-6.3% | $1.99B+53.5% | $1.29B+34.8% | $959.51M+15.8% | $828.66M-17.8% | |
| Price / sales | 22.9×+4.2× | 18.7×+9.1× | 9.6×+1.8× | 7.8×-1.1× | 8.9×-4.3× | |
| Price / book | 11.4×+4.0× | 7.4×+3.4× | 4×+1.2× | 2.9×+0.3× | 2.6×-0.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Zymeworks's ratios come from?
- Every ratio is computed from Zymeworks's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.